Abstract On November 18, 2004, erlotinib (Tarceva®; OSI Pharmaceuticals, Inc., Melville,
NY, http://www. osip. com, and Genentech, Inc., South San Francisco, CA, http://www. gene …

Abstract Purpose: To describe the Food and Drug Administration (FDA) review and approval
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …

7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …

BACKGROUND:: Erlotinib is an oral tyrosine kinase inhibitor, 1026 targeting the human
epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US …

Erlotinib (Tarceva) is a reversible and highly specific inhibitor of epidermal growth factor
receptor (EGFR) tyrosine kinase. Phase I studies established a fixed daily oral dose of 150 …

Abstract Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a
member of a class of targeted anticancer drugs that inhibit the activity of the epidermal …

BACKGROUND. Preclinical studies have suggested that erlotinib at high doses may inhibit
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …

Abstract Erlotinib (OSI-774; Tarceva™) is an orally available, highly specific epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor. The results of 3 phase II studies with …

Background We conducted a randomized, placebo-controlled, double-blind trial to
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …

Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …